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yocardial Infarction, Viral
nfection, and the Cytoskeleton
inal Common
athways of a Common Disease?*
effrey A. Towbin, MD, FACC,†‡§
atteo Vatta, PHD†
ouston, Texas
yocardial infarction (MI) is a major cause of morbidity
nd mortality in adults worldwide and is believed to result
rom an acute coronary syndrome in most affected indi-
iduals (1). In subjects with MI caused by acute coronary
yndrome, the coronary obstruction leads to ischemia,
nd the result is cell death, fibrosis, and ultimately an
schemic cardiomyopathy or a serious rhythm distur-
ance. The underlying etiologies leading to coronary
bstruction are thought to include atherosclerosis in most
nstances, although infections have also been speculated
o play a role (2). This includes chlamydia, viruses such
s enteroviruses, and other agents. However, the exact
echanisms responsible for this form of MI are not well
emonstrated.
See page 2207
In this issue of the Journal, Andréoletti et al. (3) provide
vidence supporting the concept that infectious causes of
cute MI and sudden death exist, are potentially common,
nd occur owing to disruption of a “final common pathway”
f myocardial function (4). The authors investigated the
ndomyocardial tissues of 50 patients who died suddenly of
cute MI and compared the results with samples obtained
rom 50 control subjects without evidence of cardiovascular
isease and 50 matched subjects with noncoronary chronic
ardiomyopathy. Studies performed focused on the presence
r absence of enteroviral ribonucleic acid genomes and VP1
apsid protein from coxsackievirus B in these tissues, as well
s the effect of this virus on the protein structure of the
yocardium. Specifically, the authors analyzed dystrophin
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Departments of †Pediatrics (Cardiology), ‡Medicine (Cardiovascularc
ciences), and §Molecular and Human Genetics, Baylor College of Medicine and
exas Children’s Hospital, Houston, Texas.rotein in the myocardium as well as the structural integrity
f the cardiomyocyte sarcolemma, the cell membrane of the
yocardial cell, using immunohistochemistry. Their results
howed that 40% of patients with acute MI had evidence of
nteroviral infection of the myocardium compared with 4%
f control subjects without heart disease and 8% of those
ith nonischemic cardiomyopathy. All patients with evi-
ence of enteroviral ribonucleic acid in the heart exhibited
P1 protein as well, providing evidence of viral protein
ynthesis activity, and these sequences showed strong ho-
ology to coxsackievirus B2 and B3 serotypes (3). Further-
ore, immunohistochemical analysis of the endomyocardial
issue using dystrophin antibody to the rod region demon-
trated disruption of the sarcolemmal localization of dystro-
hin in the same tissue areas infected by these viruses. The
uthors conclude that active coxsackievirus in the heart
ignificantly contributes to the pathogenesis of acute MI by
ocal disruption of dystrophin in the cardiomyocytes of
hese patients (3).
Does this make sense? Is there other supporting evidence
or this claim? Let’s take a look. Dystrophin is a rod-shaped
ytoplasmic protein in muscle that connects the cytoskele-
on of a muscle fiber to the surrounding extracellular matrix
hrough the sarcolemma at the carboxy-terminal end (C-
erminus) and to the sarcomere, the contractile apparatus of
uscle, at the amino-terminal end (N-terminus). This large
rotein, which has a molecular weight of 427 KDa and is
omposed of 3,684 amino acids, is encoded by one of the
argest genes in humans, measuring 2.5 megabases of
eoxyribonucleic acid. The protein has an N-terminus that
inds to the sarcomere via an actin-binding domain, a rod
egion composed of spectrin-like repeat sequences with
nterspersed hinge regions, and a C-terminus that binds to
he sarcolemma via a group of dystrophin-associated pro-
eins, including syntrophin and beta-dystrogylycan, as well
s interacting with ion channels such as Nav 1.5, the cardiac
odium channel encoded by the SCN5A gene (5–7). Dys-
rophin plays a variety of roles, including membrane stabil-
ty, force transduction, and resistance to mechanical stress.
hen disrupted, dystrophin leads to skeletal muscle and
ardiac dysfunction, as seen in such disorders as Duchenne
nd Becker muscular dystrophies and X-linked dilated
ardiomyopathy, X-linked disorders caused by mutations in
he dystrophin gene (7). Mutations in this gene lead to loss
f dystrophin protein function, disruption of its binding to
he dystrophin-associated proteins and sarcomeric proteins,
embrane instability and permeability, and loss of force
ransduction. These disruptions in function are further
isturbed by mechanical stress, ultimately leading to poten-
ially irreversible skeletal myopathy and cardiomyopathy. In
he latter case, heart failure and sudden death are common
ccompaniments. Interestingly, the very same events occur
hen dystrophin is disrupted by acquired disease, especially
iral-induced myocarditis. Badorff et al. (8) first showed that
oxsackievirus B3 disrupts dystrophin in myocardial infec-
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egion due to the cleavage of dystrophin by enteroviral
rotease 2A, which is encoded within the coxsackievirus B
enome. This cleavage leads to the same pathophysiologic
bnormalities seen in the genetic form of dystrophinopathy,
ith the resultant myocardial dysfunction and heart failure or
udden death ensuing. In some cases of Duchenne muscular
ystrophy, Becker muscular dystrophy, X-linked dilated car-
iomyopathy, and coxsackie-induced myocarditis, MI has been
dentified (9). In addition, ventricular arrhythmias and atrio-
entricular block also occur in these patients, and we have
rovided evidence that this is likely due to disturbed ion
hannel function, the “final common pathway” of arrhythmias
10). Thus, the work described by Andréoletti et al. (3)
ecapitulates these clinical disorders.
Previously, we have shown that this disruption in dystro-
hin may be reversible (11,12). Using left ventricular assist
evice (LVAD) therapy, which reduces mechanical stress
nd the inflammatory cascade, favorable remodeling of
ystrophin was seen, and favorable remodeling of the heart
ith improvement in ventricular function and normaliza-
ion of ventricular size and rhythm occurred. In addition, we
ave shown that coronary obstruction can occur in patients
ith myocardial viral infection and that some cases of
oronary-induced ischemic cardiomyopathy have dystrophin
isruption, and that it, too, is reversible in some LVAD-
reated patients. Therefore, the elegant study by Andréoletti
t al. (3) confirms these previously published studies and
xtends the findings to now include the common human
isorder, MI, a leading cause of death and disability.
What does this mean? There are many “take-home
essages” that this work provides. First, the concept that
ystrophin plays a major role in cardiovascular function and
ysfunction and that it is a key intermediary in the “final
ommon pathway of cardiomyopathy” is further clarified
nd supported (4,13). In addition, these disorders, whether
enetically inherited or acquired, appear to result via the
ame routes (14). Coronary arteries may become obstructed
nd lead to ischemia due to atherosclerosis based on
holesterol and lifestyle, but another significant etiology is
nfectious in nature. Whether this is due to genetic under-
innings such as mutations or polymorphisms in receptor
roteins or other key “virulence factors” remains to be seen,
ut it is possible that these acquired diseases are genetically
predestined” (15). Further studies regarding this are war-
anted to risk-stratify and provide individualized medical
dvice to patients and families in this molecular era. Finally,
ould this work provide us with novel treatment strategies to
mprove the health and outcomes of humans? The data
egarding LVAD therapy could give important insights and
uggests that “mechanical stress” reduction therapies may be
arranted (11,12). Could this be one of the actions of
eta-blockers and angiotensin-convertin enzyme inhibitors
n the favorable outcomes of cardiomyopathy and heart
ailure patients? Could protease inhibitors be useful adjunc-
ive therapies? Is this why human immunodeficiency virusHIV)-infected subjects no longer appear to be at high risk
or cardiovascular-related morbidity and mortality? We
reviously showed that the coxsackievirus genome was
nvolved in the cardiomyopathy of HIV-infected patients
nd that the HIV genome was rarely seen (16). Would
accination be useful, as it was for another enterovirus,
oliovirus, or in mumps-induced endocardial fibroelastosis
17)? Finally, could medical therapies such as intravenous
amma-globulin or interferon be useful to treat patients
ith coronary syndromes and ischemic heart disease, as they
ave been in myocarditis (18,19)?
The work by Andréoletti et al. (3) opens many new doors
n our understanding of MI, ischemic heart disease, heart
ailure, and sudden death and could become a classic
aradigm-shifting concept that leads to better outcomes and
eduction in the human burden related to coronary artery
isease. It is time to start considering new care options for
hose with coronary syndromes and time to consider the
evelopment of preventive strategies based on this infectious
rocess.
eprint requests and correspondence: Dr. Jeffrey A. Towbin,
rofessor and Chief, Pediatric Cardiology, Texas Children’s Hos-
ital, 6621 Fannin Street, MC 19345-C, Houston, Texas 77030.
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